STOCKHOLM, May 23, 2019 /PRNewswire/ -- BioArctic AB (publ)
(Nasdaq Stockholm: BIOA B) announced today that the company has
recruited the internationally renowned scientist Dr. Per-Ola
Freskgård to strengthen BioArctic's development of its technology
platform to facilitate passage of antibodies and other biologics
across the blood-brain barrier. The objective with BioArctic's
novel technology is to be able in the future to apply it to the
company's own antibodies, and also for other companies to apply it
in development of their antibodies. Through the recruitment of Dr.
Freskgård, BioArctic further strengthens its capabilities in the
neuroscience therapeutic area, antibody engineering and blood-brain
barrier competence.
Dr. Freskgård was most recently Vice Director, Distinguished
Scientist and Group Head Neurovascular Biology at the Roche
Innovation Center in Basel where
he was responsible for the implementation of new technologies to
develop biologic drugs for neurological disorders. Previously, Dr.
Freskgård has held several positions within academia and industry,
for example at AstraZeneca and Novo Nordisk, with focus on
developing new therapies within the central nervous system. For the
last 15 years, Dr. Freskgård has been active in research around new
treatments for Alzheimer's disease and other neurodegenerative
diseases. Today, Dr. Freskgård is one of the world's leading
experts on mechanisms that increase the passage of biologic drugs
across the blood-brain barrier.
The blood-brain barrier controls the exchange of substances
between the blood stream and the brain. It protects the brain from
toxins and other pathogens, but it may also limit the delivery of
therapeutic agents to the brain. In collaboration with Uppsala University, BioArctic is developing novel
technologies to increase the passage of antibodies over the
blood-brain barrier. BioArctic and Uppsala
University recently received a grant from Sweden's Innovation Agency, Vinnova, to fund a
collaboration project aimed at developing multi-specific antibodies
with a transporter to facilitate passage across the blood-brain
barrier. The recruitment of Dr. Freskgård as an expert in the field
is a further step in BioArctic's work in this area.
"That Per-Ola Freskgård, a world leading scientist on
technologies to facilitate the passage of biologics across the
blood-brain barrier, now has chosen to join BioArctic is a
recognition of the high quality research at BioArctic. This expert
recruitment further strengthens our efforts in this area. Although
the research is currently at an early stage, we believe that this
technology has a huge potential and could make a significant
difference for patients with a range of different diseases," said
Gunilla Osswald, CEO of
BioArctic.
For more information, please contact:
Gunilla Osswald, PhD, CEO,
BioArctic AB
E-mail: gunilla.osswald@bioarctic.se
Telephone:
+46-8-695-69-30
This information was submitted for publication at 8:00 a.m. CET on May 23,
2019.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma
company focusing on disease-modifying treatments and reliable
biomarkers and diagnostics for neurodegenerative diseases, such as
Alzheimer's disease and Parkinson's disease. The company also
develops a potential treatment for Complete Spinal Cord Injury.
BioArctic focuses on innovative treatments in areas with high unmet
medical needs. The company was founded in 2003 based on innovative
research from Uppsala University,
Sweden. Collaborations with
universities are of great importance to the company together with
its strategically important global partners in the Alzheimer
(Eisai) and Parkinson (AbbVie) projects. The project portfolio is a
combination of fully funded projects run in partnership with global
pharmaceutical companies and innovative in-house projects with
significant market- and out-licensing potential. BioArctic's
B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For
more information about BioArctic, please visit
www.bioarctic.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/bioarctic/r/bioarctic-strengthens-its-blood-brain-barrier-technology-platform-with-world-leading-scientist-recru,c2823172
The following files are available for download:
https://mb.cision.com/Main/9978/2823172/1050392.pdf
|
PDF
|